Shots: FDA’s PDAC & DSaRM has jointly voted (17yes -1 no) for no favorable risk profile of Zulresso for PPD patients The positive voting results for Zulresso is in response of collective data from three PBO based studies, testing safety & efficacy. The P-III trial for Zulresso is completed with NDA submission, under review by […]Read More
